Ed Kaye, former CEO of Sarepta Therapeutics, is stepping down from his current role as chief executive of a Boston-area ...

The administration’s bombing campaign against the Iran-backed group is running up against America's political and industrial ...

Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company. Stoke on Tuesday said Ian Smith, a board member since September ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

As the Trump administration’s hardline stance on immigration fuels large-scale arrests, schools around the country continue ...

A teacher's battle with skin cancer inspired her students to raise funds for a hospital charity. Pupils from Orme Academy in ...

Eric Bocat has told fan's that the Stoke City is united and ready to push for their place in the Championship after another ...

Michael O'Neill says the emergence of Conor Bradley helped "reignite" his enthusiasm on his return to the Northern Ireland ...

BEDFORD, Mass. - Stoke Therapeutics, Inc. (NASDAQ: STOK) shares dropped 4.1% after the biotechnology company announced its CEO Edward M. Kaye will step down, overshadowing better-than-expected fourth ...